If the annual number comes in at the higher end, of around $85m, then the PE is 13.x.
I would have thought that this is a tad too low. As we have seen yesterday, any +ve news that could impact dose sales will bounce the SP upwards.
Confirmation of the RHS story from Ricky, and, or from RESIN would be a kicker in my book.
An NCCN recommendation to seperate treatment based on the source would be a bigger kicker, and I believe this is in progress. However they do not work in CAFA time scales
With both, I could see the SP going to the mid to high 20s as there would be a rerating of the the stock with the expected PE going back to the high teens, or even the 20s.
When the FDA give SRX the PMA extension for HCC, or better pan-liver, again we will see a rerating of the stock.
Can they make the $85m number? My view is that with a new senior management team they would be most foolish to put their balls on the line with a number they can't meet, assuming no black swan events.
Thus I conclude that the forward PE of less than 14, allows for some more upward movement in the SP. It will one most interesting to see which analyst comes out with the first report, or maybe we will have to wait until the results are published in 5 weeks time.
SRX Price at posting:
$17.83 Sentiment: Buy Disclosure: Held
